Reverse merger adds HQ, expands Averion reach (BizJournals)
Averion Inc., a Framingham clinical research organization with a track record of approvals from the U.S. Food and Drug Administration for some 33 treatments, has completed a $25 million reverse merger that gives it control of two other firms providing related services, expands its reach to other research hot spots, and takes the company public.

Additional NanoCrystal(R) Technology Patent Issued Covering Par's Megace(R) ES (RedNova)
SPRING VALLEY, N.Y., Sept. 5 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that a new patent has been issued by the U.S.

Additional NanoCrystal(R) Technology Patent Issued Covering Par's Megace(R) ES (PR Newswire via Yahoo! Finance)
Par Pharmaceutical Companies, Inc. today announced that a new patent has been issued by the U.S. Patent and Trademark Office relating to Megace ES 625 mg/5 mL oral suspension, which utilizes Elan's NanoCrystal Technology delivery system*.